Individuals who are either patients with IDs or those not formally diagnosed with an ID but at high risk of developing one or more IDs in the near future.

How do you know if you are vulnerable to suffering a poor health outcome if you were to develop an acute inflammatory condition such as COVID?

How do you know if you have a genetic susceptibility for chronic inflammatory disease?

How do you know if you are actually developing it?

Clinicians and other health care practitioners responsible for the care of patients either with or at risk of developing IDs.

Clinicians caring for patients with IDs lack reliable and accessible tools to distinguish between the different possible types of immune dysfunction in patients with syndromic IDs. This leads to a “trial and error” approach to select anti-inflammatory treatments for newly diagnosed patients and the use of therapies that alleviate symptoms rather than treat the root cause of disease. 

Biopharma companies developing anti-inflammatory therapeutics.

Developing drugs for chronic inflammatory diseases and vaccines for acute IDs is a challenging, lengthy, and expensive process.
Currently, biopharma companies have limited tools to select patients with the right disease state and to provide reliable, quantitative evidence of drug efficacy in clinical trials to convince regulators.